Bimekizumab Demonstrated Long-Term Maintenance of Complete or Almost Complete Skin Disease Resolution for Psoriasis Patients in BE ABLE 2 Extension Study

New Data Affirms Strength of UCB Immuno-Dermatology Portfolio

UCB presents latest research at 2018 American Epilepsy Society Annual Meeting demonstrating neurology commitment and leadership 

UCB tracking well towards full year financial outlook

Bimekizumab Showed Sustained Improvements in Both Joint and Skin Outcomes for Psoriatic Arthritis Patients

UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus

• Oral presentation of results from C-AXSPAND, the first Phase 3 study to follow non-radiographic axial spondyloarthritis (nr-axSpA) patients for 52 weeks, demonstrated positive results for CIMZIA^®(certolizumab pegol) in this patient population when added to common background medications

On World Osteoporosis Day, Survey Finds the Impact of Fractures Due to Osteoporosis is Being Ignored

UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis into Confirmatory Development Phase

FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters